
    
      The purpose of the study is to determine whether the addition of the experimental mucinous
      glycoprotein 1 (MUC1) antigen-specific cancer immunotherapy tecemotide (L-BLP25) to hormonal
      treatment is effective in prolonging progression-free survival in postmenopausal women with
      endocrine-sensitive inoperable locally advanced, recurrent or metastatic breast cancer.
    
  